PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis: Erratum

Kangpeng Jin, Yang Liu, Yuze Shi, Haitian Zhang, Yuanyuan Sun, Guangyan Zhangyuan, Fei Wang, Weiwei Yu, Jincheng Wang, Xuewen Tao, Xin Chen, Wenjie Zhang, Beicheng SunTheranostics 2022 · DOI · OpenAlex

Abstract

This corrects the article DOI: 10.7150/thno.42658.

Introduction

Nonalcoholic Steatohepatitis (NASH) is a severe progression of fatty liver disease characterized by chronic inflammation and hepatocyte damage. A central challenge in hepatology is identifying the molecular mechanisms that trigger the transition from simple steatosis (fat accumulation) to NASH. Research has identified PTPROt (Protein tyrosine phosphatase receptor type O truncated isoform) as a critical mediator of this inflammatory response, specifically within liver macrophages. This erratum addresses a statistical reporting error regarding clinical correlations while reaffirming PTPROt's role as a key driver of NASH-related inflammation.

Methods and Patient Cohort

The study utilized a human cohort of 110 individuals categorized by disease severity: Normal ($n=24$), Simple Steatosis ($n=32$), and NASH ($n=54$). To investigate PTPROt's role, the researchers employed:

  • Immunofluorescence Microscopy: To co-localize PTPROt with CD68+ macrophages in human liver sections.
  • qRT-PCR: To quantify PTPROt mRNA levels in macrophages isolated from liver tissue.
  • Clinical Correlation Analysis: Using Spearman’s rank correlation to relate PTPROt expression with clinical markers including BMI, triglycerides (TG), and liver enzymes (ALT, AST, and γ-GT).

Results: PTPROt Expression and Clinical Significance

The data demonstrates a clear stepwise increase in PTPROt expression that mirrors the progression of liver disease. PTPROt levels are significantly higher in NASH patients compared to those with simple steatosis or healthy controls.

PTPROt expression and clinical correlations in human liver tissues.

Key Insights

  • Macrophage-Specific Upregulation: PTPROt is specifically elevated in liver macrophages, which act as primary immune sentinels. Its activation suggests a direct mechanism for escalating inflammation via the NF-κB pathway.
  • Strong Clinical Correlation: PTPROt mRNA levels correlate significantly ($P < 0.0001$) with markers of liver damage and metabolic health:
  • ALT (Alanine aminotransferase): $r = 0.8391$
    • AST (Aspartate aminotransferase): $r = 0.8739$
    • γ-GT (γ-glutamyl transpeptidase): $r = 0.8624$ (Corrected value)
    • BMI: $r = 0.6307$
    • Serum Triglycerides: $r = 0.7875$

Conclusion

This erratum corrects a data swap between ALT and γ-GT correlation values in the original publication. The corrected analysis confirms that PTPROt expression in macrophages remains a robust and highly significant indicator of NASH severity and clinical liver dysfunction. These findings reinforce the potential of PTPROt as both a diagnostic biomarker and a therapeutic target for mitigating inflammation in nonalcoholic fatty liver disease.

Summary updated

Abstract

[This corrects the article DOI: 10.7150/thno.42658.].
BibTeX
@inproceedings{jin2022ptprot,
  author = {Kangpeng Jin and Yang Liu and Yuze Shi and Haitian Zhang and Yuanyuan Sun and Guangyan Zhangyuan and Fei Wang and Weiwei Yu and Jincheng Wang and Xuewen Tao and Xin Chen and Wenjie Zhang and Beicheng Sun},
  title = {{PTPROt aggravates inflammation by enhancing NF-κB activation in liver macrophages during nonalcoholic steatohepatitis: Erratum}},
  booktitle = {Theranostics},
  year = {2022},
  doi = {10.7150/thno.73372},
}
Figure